1. Hancock WW, Muller WA, Cotran RS. Interleukin 2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes, and monocyte cell lines. J Immunol (1987); 138: 185–91.
2. Rosenberg SA, Mule JJ, Spiess PL, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneus tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 1985; 161: 1169–88.
3. Lotze MT, Matory YL, Rayner AA et al. lClinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 1986; 58: 2764–72.
4. Forni G, Giovarelli M, Santoni A. Lymphokine-activated tumor inhibitedin vivo. 1. The local administration of interleukin 2 triggers non reactive lymphocytes from tumor-bearing mice inhibit tumor growth. J Immunol 1985; 134: 1305–11.
5. Budenik J, Indrova M. The antitumor efficacy of human recombinant interleukin-2. Cancer Immunol Immunother 1987; 24: 269–71.